Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Alkahest Doses First Subject in Phase 2 GRF6021 Trial

americanpharmaceuticalreviewDecember 05, 2018

Tag: GRF6021 Trial , Alkahest , Parkinson's disease , cognitive impairment

PharmaSources Customer Service